Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Laurent Hocqueloux"'
Autor:
Delphine Planas, Isabelle Staropoli, Vincent Michel, Frederic Lemoine, Flora Donati, Matthieu Prot, Francoise Porrot, Florence Guivel-Benhassine, Banujaa Jeyarajah, Angela Brisebarre, Océane Dehan, Léa Avon, William Henry Bolland, Mathieu Hubert, Julian Buchrieser, Thibault Vanhoucke, Pierre Rosenbaum, David Veyer, Hélène Péré, Bruno Lina, Sophie Trouillet-Assant, Laurent Hocqueloux, Thierry Prazuck, Etienne Simon-Loriere, Olivier Schwartz
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract The unceasing circulation of SARS-CoV-2 leads to the continuous emergence of novel viral sublineages. Here, we isolate and characterize XBB.1, XBB.1.5, XBB.1.9.1, XBB.1.16.1, EG.5.1.1, EG.5.1.3, XBF, BA.2.86.1 and JN.1 variants, representing
Externí odkaz:
https://doaj.org/article/8234f50bbc5043a1a52a4adceb8cfad0
Autor:
Cassidy A. Gutner, Laurent Hocqueloux, Celia Jonsson‐Oldenbüttel, Linos Vandekerckhove, Berend J. vanWelzen, Laurence Slama, María Crusells‐Canales, Julián Olalla Sierra, Rebecca DeMoor, Jenny Scherzer, Mounir Ait‐Khaled, Gilda Bontempo, Martin Gill, Natasha Patel, Ronald D'Amico, Kai Hove, Bryan Baugh, Nicola Barnes, Monica Hadi, Emma L. Low, Savita Bakhshi Anand, Alison Hamilton, Harmony P. Garges, Maggie Czarnogorski
Publikováno v:
Journal of the International AIDS Society, Vol 27, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Cabotegravir plus rilpivirine (CAB + RPV) is the first complete long‐acting (LA) regimen recommended for maintaining HIV‐1 virological suppression. Cabotegravir And Rilpivirine Implementation Study in European Locations (CAR
Externí odkaz:
https://doaj.org/article/cf663c19fbc04c13b44fe74a60666e97
Autor:
Cyril Planchais, Luis M. Molinos-Albert, Pierre Rosenbaum, Thierry Hieu, Alexia Kanyavuz, Dominique Clermont, Thierry Prazuck, Laurent Lefrou, Jordan D. Dimitrov, Sophie Hüe, Laurent Hocqueloux, Hugo Mouquet
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract HIV-1 infection causes severe alterations of gut mucosa, microbiota and immune system, which can be curbed by early antiretroviral therapy. Here, we investigate how treatment timing affects intestinal memory B-cell and plasmablast repertoire
Externí odkaz:
https://doaj.org/article/721b42fa56454c4cb5fce2e7f31a7b08
Autor:
Charles de Roquetaillade, Cédric Laouenan, Jean-Paul Mira, Carine Roy, Marie Thuong, Élie Azoulay, Didier Gruson, Frédéric Jacobs, Juliette Chommeloux, François Raffi, Laurent Hocqueloux, Patrick Imbert, Vincent Jeantils, Jean-Luc Delassus, Sophie Matheron, Catherine Fitting, Jean-François Timsit, Fabrice Bruneel
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract The increase in worldwide travel is making imported malaria a growing health concern in non-endemic countries. Most data on the pathophysiology of malaria come from endemic areas. Little is known about cytokine profiles during imported malar
Externí odkaz:
https://doaj.org/article/14b318b8a92a479ba7232d21bbbf830a
Autor:
Delphine Planas, Timothée Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Françoise Porrot, Piet Maes, Ludivine Grzelak, Matthieu Prot, Said Mougari, Cyril Planchais, Julien Puech, Madelina Saliba, Riwan Sahraoui, Florent Fémy, Nathalie Morel, Jérémy Dufloo, Rafael Sanjuán, Hugo Mouquet, Emmanuel André, Laurent Hocqueloux, Etienne Simon-Loriere, David Veyer, Thierry Prazuck, Hélène Péré, Olivier Schwartz
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
In this work, Planas et al. report that Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 escape neutralization from monoclonal antibodies, and sera from vaccinated individuals with or without Omicron BA.1/2 or BA.5 breakthrough infection.
Externí odkaz:
https://doaj.org/article/9c8be56ed653485d87b24ff59791518f
Autor:
Quentin Clairon, Mélanie Prague, Delphine Planas, Timothée Bruel, Laurent Hocqueloux, Thierry Prazuck, Olivier Schwartz, Rodolphe Thiébaut, Jérémie Guedj
Publikováno v:
PLoS Computational Biology, Vol 19, Iss 8, p e1011282 (2023)
Because SARS-CoV-2 constantly mutates to escape from the immune response, there is a reduction of neutralizing capacity of antibodies initially targeting the historical strain against emerging Variants of Concern (VoC)s. That is why the measure of th
Externí odkaz:
https://doaj.org/article/7a6ead9f887c452db7569b3b23028047
Autor:
Luis M. Molinos-Albert, Valérie Lorin, Valérie Monceaux, Sylvie Orr, Asma Essat, Jérémy Dufloo, Olivier Schwartz, Christine Rouzioux, Laurence Meyer, Laurent Hocqueloux, Asier Sáez-Cirión, Hugo Mouquet, ANRS VISCONTI Study Group
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
A rare sub-population of people living with HIV-1 experience long-lasting viral remission after interrupting antiretroviral therapy and are considered post-treatment controllers. Here the authors characterise the humoral immune response to HIV-1 in a
Externí odkaz:
https://doaj.org/article/8c2bb6fda8ec43b2afd6cfd0349d774c
Autor:
Pauline Trémeaux, Frédéric Lemoine, Adeline Mélard, Marine Gousset, Faroudy Boufassa, Sylvie Orr, Valérie Monceaux, Olivier Gascuel, Olivier Lambotte, Laurent Hocqueloux, Asier Saez-Cirion, Christine Rouzioux, Véronique Avettand-Fenoel
Publikováno v:
Microbiology Spectrum, Vol 11, Iss 1 (2023)
ABSTRACT In the search for control of human immunodeficiency virus type 1 (HIV-1) infection without antiretroviral therapy, posttreatment controllers (PTCs) are models of HIV remission. To better understand their mechanisms of control, we characteriz
Externí odkaz:
https://doaj.org/article/8e62f5197b554293924fa6c48469dcf9
Autor:
Nolwenn Hall, Clotilde Allavena, Christine Katlama, Alexandra Jobert, Jean-Michel Molina, Eric Cua, Firouzé Bani-Sadr, Laurent Hocqueloux, Claudine Duvivier, Dominique Merrien, Hitoto Hikombo, Elisabeth André-Garnier, Aurélie Gaultier, François Raffi, the QDISS Study Group
Publikováno v:
AIDS Research and Therapy, Vol 19, Iss 1, Pp 1-6 (2022)
Abstract Background Raltegravir (RAL) has favorable tolerability and safety profile, with few and manageable drug interactions. The use of RAL 1200 mg once daily (qd) for first-line therapy is well established. We assessed efficacy and safety of RAL
Externí odkaz:
https://doaj.org/article/92db89510b02477094df275432b25b0c
Autor:
Nell Saunders, Delphine Planas, William H. Bolland, Christophe Rodriguez, Slim Fourati, Julian Buchrieser, Cyril Planchais, Matthieu Prot, Isabelle Staropoli, Florence Guivel-Benhassine, Françoise Porrot, David Veyer, Hélène Péré, Nicolas Robillard, Madelina Saliba, Artem Baidaliuk, Aymeric Seve, Laurent Hocqueloux, Thierry Prazuck, Felix A. Rey, Hugo Mouquet, Etienne Simon-Lorière, Timothée Bruel, Jean-Michel Pawlotsky, Olivier Schwartz
Publikováno v:
EBioMedicine, Vol 77, Iss , Pp 103934- (2022)
Summary: Background: SARS-CoV-2 lineages are continuously evolving. As of December 2021, the AY.4.2 Delta sub-lineage represented 20 % of sequenced strains in the UK and had been detected in dozens of countries. It has since then been supplanted by O
Externí odkaz:
https://doaj.org/article/4dfcddff1cd1483b863fbf185e40d85f